Bringing together leaders from the public and private sectors in Singapore, as well as domestic and international academic experts, the Healthcare PPP Forum will address the importance of public-private partnerships and their role in solving complex public policy problems. Panelists and speakers will touch on issues including elderly care, the rise of non-communicable diseases (NCDs), and the role of the public in successful public-private partnerships.
9.00am: Welcome Remarks by Dr Adrian Kuah, Head, Case Study Unit
9.05am: Opening Remarks by Prof M. Ramesh, Professor & UNESCO Chair on Social Policy Design in Asia
9.15am: Panel 1: will explore upcoming trends and benefits associated with PPPs in healthcare. The panel features speakers with diverse fields of expertise and will offer insights on the relative strengths of government, private sector, and the public as partners in a public-private partnership.
- Ms Audrey Tong, Senior Deputy Director, Corporate & Industry Partnerships, Health Promotion Board, Singapore
- Dr Joseph D. Mocanu, Principal, Life Sciences and Digital Health, Oliver Wyman, Asia
Chairperson: Prof M Ramesh, Professor & UNESCO Chair on Social Policy Design in Asia, Lee Kuan Yew School of Public Policy
Networking Tea Break10.45am:
Case Studies Presentation by Prof Alan M. Trager, Founder and Director of the Public-Private Partnerships Initiative
Panel 2: will focus on the specific skills and frameworks necessary to govern and manage a successful PPP. Panelists will discuss these cases and how they can be used as learning resources to build PPP capacity.
- Assoc Prof. Eduardo Araral, Vice Dean (Research), Co-Director, Institute of Water Policy & Associate Professor, Lee Kuan Yew School of Public Policy
- Ms Pang Sze Yunn, Head, Population Health Management, Philips ASEAN Pacific
- Dr Mooppil Nandakumar, Director of Clinical Services, NKF Singapore
Chairperson: Prof Alan M. Trager, Founder and Director of the Public-Private Partnerships Initiative
Closing Remarks by Mr Raphael Ho General Manager for Singapore, Malaysia and Brunei, Amgen12.10pm:
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on https://twitter.com/amgen